Skip to content

Shares (Basic) at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
97.5M+21.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
99.9M+21.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
63.1M+9.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
66.4M+52.1%
Nuvation Bio logo
Nuvation BioNUVB
347.3M+2.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
100.6M+4.5%

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s shares (basic)?
Nurix Therapeutics, Inc. (NRIX) reported shares (basic) of 110.1M in Q4 2025.
How has Nurix Therapeutics, Inc.'s shares (basic) changed year-over-year?
Nurix Therapeutics, Inc.'s shares (basic) increased by 31.7% year-over-year, from 83.6M to 110.1M.
What is the long-term trend for Nurix Therapeutics, Inc.'s shares (basic)?
Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s shares (basic) has grown at a 21.4% compound annual growth rate (CAGR), from 189.1M to 338.3M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.